Merck & Co. (MRK)
(Delayed Data from NYSE)
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.90 +0.02 (0.02%) 4:34 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.90 +0.02 (0.02%) 4:34 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA
by Zacks Equity Research
The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.
The Zacks Analyst Blog Highlights Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser
by Zacks Equity Research
Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser are part of the Zacks top Analyst Blog.
Top Stock Reports for Merck, Thermo Fisher Scientific & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Thermo Fisher Scientific Inc. (TMO) and American Express Company (AXP).
AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab
by Zacks Equity Research
AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.
A Look at Pharma ETFs Post Q4 Earnings
by Sweta Killa
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie Q4 Preview: What's in Store?
by Derek Lewis
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge.
Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.
Goldilocks Econ Data Presides Over Pre-Market
by Mark Vickery
We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.
Merck (MRK) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others
by Zacks Equity Research
Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
by Zacks Equity Research
Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.
Why Merck & Co. (MRK) Might Surprise This Earnings Season
by Zacks Equity Research
Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck (MRK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV